Monitor Endocrine / Vitamin Watchlist

Abstract

Calcium/PTH/vitamin D and thyroid are watchlist items, not active alarms. Total calcium is high-normal and stable, PTH normalized after vitamin-D repletion, 25(OH)D is already sufficient, and April 2026 TSH normalized after a prior high-normal spike. The plan is paired-axis monitoring, vitamin-D consistency without escalation, optional thyroid antibodies only if the signal recurs or after higher-priority branches settle, and no K2/thyroid speculation as a substitute for echo or ASCVD management.

calcium · PTH · parathyroid · vitamin-D · vitamin-K2 · hypercalcemia · vascular-calcification · thyroid · tsh · subclinical-hypothyroidism · TPO-antibodies

Endocrine / Vitamin Watchlist

Current conclusion

This cluster is a watchlist, not a current endocrine diagnosis.

Calcium/PTH/vitamin D:

total calcium has been high-normal for years, with one older 2.55 mmol/L value in 2015 and recent values around 2.47-2.50 mmol/L
albumin has sometimes been high, which can push total calcium up without proving high ionized calcium
PTH was elevated once in 2022 with only modest vitamin-D status, then normalized by 2024
25(OH)D is about 105 nmol/L, already sufficient and below toxicity-concern ranges
current NOW product: 1,000 IU D3 + 45 mcg K2 as MK-4 per capsule; 2/day = 2,000 IU D3 + 90 mcg MK-4

Thyroid:

the old “monotonic rise” story is broken: TSH moved 1.5 (2015) / 1.4 (2018) / 2.0 (2024-08) / 2.65 (2025-10) / 2.82 (2025-11) / 3.61 (2025-12) back down to 1.75 (2026-04)
free T4 has historically been normal
atorvastatin dose reduction from 40 mg to 20 mg occurred before normalization, but causality is unproven
true hypothyroidism can worsen atherogenic risk and possibly Lp(a)-related context, but current data do not support thyroid dysfunction as an active risk amplifier

Bottom line: maintain, pair-check if rechecking, and do not chase higher vitamin D, K2, or thyroid testing while more actionable GI/hematology/cardiovascular branches are live.

What changes the decision

Situation	Interpretation	Action
Calcium remains in range and PTH normal	Stable high-normal total calcium; no active parathyroid diagnosis	Keep D3 maintenance; monitor with routine chemistry
Repeated calcium above range or corrected/ionized calcium high	Hypercalcemia branch opens	Repeat calcium + albumin/corrected calcium + PTH + creatinine/eGFR + phosphorus + 25(OH)D; clinician review
PTH rises while calcium is normal	Secondary hyperparathyroidism or normocalcemic PHPT only after exclusions	Repeat over 3-6 months; exclude low D, kidney disease, malabsorption, hypercalciuria, and medication causes
25(OH)D rises above about 125 nmol/L, or calcium rises with D dosing	Too much D becomes plausible	Reduce/hold D3 and recheck calcium/PTH/25(OH)D with clinician input
Concern is Lp(a)-aortic valve risk	Not answered by calcium/K2 labs	Baseline echocardiogram; CAC/CCTA answer coronary plaque, not valve reassurance
TSH stays normal	Thyroid remains background monitoring	Recheck with routine follow-up, not urgent repeat
TSH rises again toward/above ~4.0 or symptoms become specific	Thyroid branch reopens	Add free T4; consider TPO antibodies; clinician interpretation
Desire to close latent autoimmune-thyroid question after higher priorities settle	TPO Ab optional	Reasonable once GI/hematology questions are less urgent

What to do now

Keep vitamin D in maintenance mode. Do not push 25(OH)D higher than the current sufficient range.
If rechecking the calcium/PTH axis, draw the paired set on the same day: calcium, albumin, PTH, 25(OH)D, phosphorus, creatinine/eGFR. Ionized calcium is useful if available.
Biomed public tariff context from 2026-05-03: serum calcium, albumin, phosphorus, PTH/iPTH, and 25(OH)D are listed; ionized calcium and serum vitamin K were not found.
K2 form/label hygiene is fine, but switching MK-4 to MK-7 is optional supplement tidying, not cardiovascular treatment.
Treat aortic-valve surveillance as an Lp(a) imaging issue: baseline echo first; K2 is not a substitute.
Thyroid: recheck TSH with routine follow-up bloodwork. Add free T4/TPO only if TSH rises again, symptoms strongly fit hypothyroidism, or the autoimmune-thyroid question is worth closing after higher-priority branches settle.

What not to do

Do not diagnose primary hyperparathyroidism from high-normal total calcium alone.
Do not ignore albumin/corrected or ionized calcium when total calcium is borderline.
Do not chase vitamin D above sufficiency; no current reason to target “higher is better.”
Do not use vitamin K2 as claimed protection against Lp(a)-related valve disease, CAC, or ASCVD events.
Do not order serum vitamin K as a routine cardiovascular marker.
Do not treat one normalized TSH fluctuation as active thyroid disease.
Do not blame atorvastatin for the old TSH rise as a conclusion; it remains plausible background context only.
Do not let thyroid/K2 speculation distract from echo, BP, ApoB/Lp(a) management, smoking cessation, GI bleeding/iron follow-up, and imaging decisions.

Evidence and owner links

Current owner: Endocrine / Vitamin Watchlist.
Absorbed detail covered here: calcium/PTH/vitamin D, vitamin K2, and TSH trend logic.

Evidence anchors retained from the absorbed pages:

Primary hyperparathyroidism evaluation/management: PMID: 36245251.
NIH ODS Vitamin D fact sheet, updated 2025: adequacy >=50 nmol/L; possible adverse associations above 125 nmol/L, especially above 150 nmol/L.
2024 Endocrine Society vitamin-D prevention guideline: PMID: 38828931.
Vitamin K vascular/calcification evidence: PMID: 37252246; PMID: 38046003; AVADEC vitamin K2 + D aortic-valve calcification RCT PMID: 35465686.
Lp(a) and calcific aortic valve disease: PMID: 37650693.
Thyroid management frame: NICE NG145, Thyroid disease: assessment and management, https://www.nice.org.uk/guidance/ng145.
NOW Foods Vitamin D3 & K2 product page: https://www.nowfoods.com/products/supplements/vitamin-d3-k2-capsules.

This is the canonical endocrine/vitamin owner. Vitamin D/K2 and TSH decisions should be read here rather than as separate pages.